Delta-9-Tetrahydrocannabinol

In 15 healthy male infrequent cannabis users given 7.5 mg or 15 mg oral THC versus placebo in a double-blind crossover design, the higher 15 mg dose acutely impaired episodic memory and learning while sparing working memory and implicit memory; subjective intoxication and liking of the drug effect were pronounced but residual effects were minimal at 24–48 hours.

In 16 healthy volunteers with modest prior cannabis exposure, a single intravenous dose of THC (1.19 mg) induced at least mild psychotomimetic or psychiatric symptoms in 94% of participants, with moderate to severe symptoms in 19%; approximately one-third still had mild symptoms 2.5 hours post-dose, and acute physical reactions were more frequent in women than men.

In 15 healthy male infrequent cannabis users given 7.5 mg or 15 mg oral THC versus placebo in a double-blind crossover design, the higher 15 mg dose acutely impaired episodic memory and learning while sparing working memory and implicit memory; subjective intoxication and liking of the drug effect were pronounced but residual effects were minimal at 24–48 hours.

In healthy volunteers performing sensory delayed discrimination tasks under THC versus placebo, THC reduced task performance and altered functional brain activation patterns in regions related to sensory processing and working memory, indicating acute disruption of delayed sensory discrimination.

In 15 healthy male infrequent cannabis users given 7.5 mg or 15 mg oral THC versus placebo in a double-blind crossover design, the higher 15 mg dose acutely impaired episodic memory and learning while sparing working memory and implicit memory; subjective intoxication and liking of the drug effect were pronounced but residual effects were minimal at 24–48 hours.

In a double-blind, randomized, cross-over study of 23 former cannabis users abstinent for at least three months, intravenous THC at 0.015 and 0.03 mg/kg produced dose-dependent deficits in fine motor control and motor timing, while gross motor performance and sustained attention were largely unaffected; subjective intoxication did not differentiate between the two active doses despite greater objective impairment.

In healthy volunteers given a modest dose of THC versus placebo, THC acutely increased anxiety symptoms and modulated right amygdala activation during fear processing, with anxiety severity correlating with baseline CB1 receptor availability in the amygdala.

In 16 healthy volunteers with modest prior cannabis exposure, a single intravenous dose of THC (1.19 mg) induced at least mild psychotomimetic or psychiatric symptoms in 94% of participants, with moderate to severe symptoms in 19%; approximately one-third still had mild symptoms 2.5 hours post-dose, and acute physical reactions were more frequent in women than men.

In 15 healthy male infrequent cannabis users given 7.5 mg or 15 mg oral THC versus placebo in a double-blind crossover design, the higher 15 mg dose acutely impaired episodic memory and learning while sparing working memory and implicit memory; subjective intoxication and liking of the drug effect were pronounced but residual effects were minimal at 24–48 hours.

In a double-blind, randomized, cross-over study of 23 former cannabis users abstinent for at least three months, intravenous THC at 0.015 and 0.03 mg/kg produced dose-dependent deficits in fine motor control and motor timing, while gross motor performance and sustained attention were largely unaffected; subjective intoxication did not differentiate between the two active doses despite greater objective impairment.

In 16 healthy volunteers with modest prior cannabis exposure, a single intravenous dose of THC (1.19 mg) induced at least mild psychotomimetic or psychiatric symptoms in 94% of participants, with moderate to severe symptoms in 19%; approximately one-third still had mild symptoms 2.5 hours post-dose, and acute physical reactions were more frequent in women than men.

In a double-blind, randomized, cross-over study of 23 former cannabis users abstinent for at least three months, intravenous THC at 0.015 and 0.03 mg/kg produced dose-dependent deficits in fine motor control and motor timing, while gross motor performance and sustained attention were largely unaffected; subjective intoxication did not differentiate between the two active doses despite greater objective impairment.